ArticleJournal of medical biochemistry2025
Predictive value of serum inflammatory factors high-sensitivity C-reactive protein combined with high level of lipoprotein-associated phospholipase A2 for the onset of ischemic stroke.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The aim of this study was to carried out an exploration of the predictive value of serum high-sensitivity C-reactive protein (hs-CRP) plus high levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) for the onset of ischemic stroke (IS). This study extends the understanding of their interplay by highlighting their mechanistic contributions to vascular inflammation and plaque instability, factors crucial in IS onset. Methods: 526 IS patients were selected as the experimental group (EG). During the same period, 463 healthy individuals served as the control group (CG). The levels of Lp-PLA2, myeloperoxidase (MPO), total cholesterol (CHO), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), hs-CRP, and serum ferritin (SF) in the serum of subjects were compared. The predictive efficacy of combination of two for the onset of IS was assessed. Results: The levels of Lp-PLA2, MPO, CHO, LDL, TG, hs-CRP, and SF in patients with IS were all markedly higher as against the CG (P<0.05). Multivariate Logistic regression analysis (MLRA) suggested that both hs-CRP and Lp-PLA2 were independently associated with the risk of IS (OR=1.334, 95% CI=1.713~1.954; 1.251, 1.011~1.921). The ROC curve analysis revealed that the predictive efficacy for IS of hs-CRP in combination with Lp-PLA2 (area under the ROC curve (AUC)=0.786) was markedly better as against hs-CRP alone (0.713) or Lp-PLA2 alone (0.698) (P<0.05). Mechanistically, their interaction may exacerbate vascular inflammation, promoting plaque instability, a crucial process in IS development. Conclusions: This study reinforces that the combined detection of hs-CRP and Lp-PLA2 significantly improves IS risk prediction by offering a more comprehensive assessment of inflammatory and atherosclerotic status. Their interplay suggests potential therapeutic targets for preventing IS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.